腾药Tengyao品牌怎么样 申请店铺

我要投票 腾药Tengyao在乌鸡白凤丸行业中的票数:564 更新时间:2025-08-04
腾药Tengyao是哪个国家的品牌?「腾药Tengyao」是 云南腾药制药股份有限公司 旗下著名品牌。该品牌发源于云南省保山市,由创始人赵丙贤在1990-06-22期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力腾药Tengyao品牌出海!将品牌入驻外推网,定制腾药Tengyao品牌推广信息,可以显著提高腾药Tengyao产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

腾药Tengyao怎么样

云南腾药制药股份有限公司(以下简称“腾药”)成立于1956年,1997年改为股份合作制企业,2011年9月在县委政府的关心支持下完成股份制改造,同年11月与北京中证万融医药投资集团实现战略合作。

历经五十多年历史积淀的腾药,目前在编在岗员工600余人(含销售人员),具备了雄厚的制药技术基础,公司在不断汲取现代科学技术的基础上具备了专业的检测手段。两者的有机结合,使“腾药”产品有了过硬的质量,造就的品种有心脉隆注射液、安宫牛黄丸、人参再造丸、六味地黄丸、六灵丸、藿香正气水、感冒疏风片、清肺抑火片等。年生产规模为2000多吨,主要剂型有注射剂、丸剂(大蜜丸、小蜜丸、水丸、水蜜丸)、片剂、颗粒剂、散剂、酒剂、酊剂、糖浆剂,国药准字批文 130个,87个品种,137个品规,均是中药、天然药物。其中,国家二类新药“心脉隆注射液”由企业与大理学院联合研制,于2007年获准生产上市,为腾药的发展注入了新的活力。

规划:发展为以心脉隆注射液为主,传统普药为辅,日化保健品为补的上市企业。

党建:公司党总支下设5个党支部,共有党员62名(其中女党员37名)。

文化:公司起源于药王宫(建于明代天启六年)——全国中医药文化宣传教育基地,整个以求健康、传健康、学健康、食健康为主。公司秉承诚信制药,争做百年腾药。公司核心使命:“为人类健康创造卓越价值”,核心价值:“顾客第一服务他人 诚信 创新”。

诚信:公司一直秉承诚信制药的优良传承,用“宁为上药三分利,莫负良医九折肱”的对联警醒着一代又一代制药人。

创新:以心脉隆注射液为主的科研课题研究、美蠊系列日化保健品开发。


Yunnan tengyao Pharmaceutical Co., Ltd. (hereinafter referred to as "tengyao") was founded in 1956, changed into a joint-stock cooperative enterprise in 1997, completed the joint-stock transformation in September 2011 with the care and support of the county Party committee and government, and achieved strategic cooperation with Beijing Zhongzheng Wanrong pharmaceutical investment group in November of the same year. After more than 50 years of historical accumulation, tengyao has more than 600 employees (including sales staff) on the job at present, with a strong pharmaceutical technology foundation, and the company has a professional testing method based on continuous learning of modern science and technology. The organic combination of the two makes the "tengyao" products have excellent quality. The varieties created are Xinmailong injection, Angongniuhuang pill, Renshen Zaizai pill, Liuwei Dihuang pill, Liuling pill, Huoxiang Zhengqi water, Ganmao Shufeng tablet, Qingfei Yihuo tablet, etc. The annual production scale is more than 2000 tons, and the main dosage forms are injection, pill (big honey pill, small honey pill, water pill, water honey pill), tablet, granule, powder, liquor, tincture, syrup. There are 130 national drug approval documents, 87 varieties, 137 product specifications, all of which are traditional Chinese medicine and natural medicine. Among them, Xinmailong injection, a national second-class new drug, was jointly developed by the enterprise and Dali University, and was approved for production and listing in 2007, which injected new vitality into the development of tengyao. Planning: to develop into a listed enterprise mainly with Xinmailong injection, supplemented by traditional general medicine and supplemented by daily chemical health products. Party Construction: the company has 5 party branches under the general Party branch, with 62 party members (including 37 female party members). Culture: the company originated in the palace of Medicine (built in the sixth year of Tianqi in Ming Dynasty) - the national base of traditional Chinese medicine culture publicity and education, focusing on health, transmission, learning and eating. The company adheres to the integrity of pharmaceutical, striving to be a century drug. The company's core mission: "to create outstanding value for human health", and its core value: "customer first, serve others and innovate with integrity". Integrity: the company has always been adhering to the good heritage of integrity pharmaceutical, with the couplet of "better for the third profit of the drug, better for the nine fold arm" to alert generations of pharmaceutical people. Innovation: Research on Xinmailong injection as the main scientific research topic, and development of Periplaneta americana series of daily chemical health products.

本文链接: https://brand.waitui.com/19813d252.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

着眼提升持有人体验,多只基金接连宣布限购

又一明星基金经理在管产品宣布限购。8月2日,永赢基金公告称,对旗下权益基金永赢睿信进行限购,并表示此次限购着眼于引导投资者理性、长期投资,有助于维持基金规模稳定,提升持有人体验。记者注意到,近期已有多只主动权益基金接连宣告限购,多为红利主题基金和量化小微盘策略基金。其中,国金量化多因子、招商成长量化选股、中信保诚多策略等量化小微盘策略基金年内已多次降低申购限额。(证券时报)

刚刚

“真金白银”积极入市,资金共振趋势或延续

随着市场风险偏好的逐步提升,多路资金正在积极入市。业内人士认为,在“险资先行”后,银行理财和公募基金有望成为下半年的重要边际力量,赚钱效应带来的资金共振趋势或延续。愈来愈多的增量资金选择借基入市。Choice数据显示,截至8月1日,近两周,沪深两市股票型ETF的周净申购份额分别超过60亿份、50亿份。同时,7月,权益类(股票型、混合型)基金的新发规模也达到347亿元,较6月的292亿元增长18.8%,新发数量环比增加26只,多只“小爆款”产品首募规模超20亿元。(上证报)

刚刚

基金净值批量超过2021年高点,多位投资老将强势回归备受瞩目

主动权益类基金正加速收复失地。在今年以来的结构性行情中,数百只基金净值迈过2021年高点。备受瞩目的是,多位投资老将焕发新“生机”。凭借对科技、创新药、新消费等领域的布局,他们旗下基金的净值强势反弹。在业内人士看来,对于投资而言,与时俱进十分关键。面对不断涌现的新技术、新趋势,只有保持敏锐度、动态调整投资方向,才能在变化中捕捉新机遇。(上证报)

刚刚

澳大利亚天然气生产商Santos与法国能源公司Engie签署纳拉布里天然气供应协议

8月4日消息,澳大利亚天然气生产商Santos与法国能源公司Engie签署不具约束力的谅解备忘录,将从纳拉布里天然气项目向澳大利亚东海岸国内市场供应天然气。项目投产后,Santos将在至少10年内每年向Engie供应高达20拍焦耳(PJ)的纳拉布里天然气 。目前,该项目还需经过最终投资决定、约束协议签署及内部各自审批。(界面)

刚刚

华泰证券港股策略:市场回调带来结构性机会

36氪获悉,华泰证券发布港股策略研报称,近期港股回调主因内外预期修正,但中期流动性宽松逻辑不改。配置上建议寻找景气改善+低估值板块,尤其强调对科技板块的配置;短期交易围绕中报业绩展开,建议关注:1)估值有性价比且景气改善的游戏和互联网电商龙头;2)前向12个月估值分位数略高但盈利兑现度高,如港股创新药及非银金融。

刚刚

本页详细列出关于腾药Tengyao的品牌信息,含品牌所属公司介绍,腾药Tengyao所处行业的品牌地位及优势。
咨询